Deep-pocketed investors have adopted a bearish approach towards Pfizer PFE, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PFE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Pfizer. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 23% leaning bullish and 76% bearish. Among these notable options, 2 are puts, totaling $155,500, and 11 are calls, amounting to $953,986.
What's The Price Target?
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $22.5 to $26.0 for Pfizer during the past quarter.
Volume & Open Interest Trends
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale trades within a strike price range from $22.5 to $26.0 in the last 30 days.
Pfizer Call and Put Volume: 30-Day Overview
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| PFE | CALL | SWEEP | BEARISH | 02/23/24 | $26.00 | $379.5K | 21.0K | 9.7K |
| PFE | CALL | SWEEP | BEARISH | 02/23/24 | $26.00 | $151.6K | 21.0K | 7.4K |
| PFE | CALL | SWEEP | BULLISH | 02/23/24 | $26.00 | $105.9K | 21.0K | 938 |
| PFE | PUT | TRADE | BEARISH | 03/21/25 | $22.50 | $105.0K | 5.3K | 1.5K |
| PFE | CALL | SWEEP | BEARISH | 02/23/24 | $26.00 | $54.6K | 21.0K | 6.5K |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.
Where Is Pfizer Standing Right Now?
- Currently trading with a volume of 14,661,685, the PFE's price is up by 0.24%, now at $27.62.
- RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
- Anticipated earnings release is in 78 days.
What The Experts Say On Pfizer
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $45.0.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
